Litcius/Paper detail

Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation

Ibiayi Dagogo‐Jack

2020Journal of Thoracic Oncology28 citationsDOIOpen Access PDF

Topics & Concepts

TrametinibDabrafenibMedicineV600ELung cancerMutationCancer researchCancerKinaseOncologyInternal medicineMelanomaMAPK/ERK pathwayVemurafenibGeneGeneticsBiologyMetastatic melanomaLung Cancer Treatments and MutationsMelanoma and MAPK PathwaysCancer Mechanisms and Therapy
Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation | Litcius